Pfizer, Innovent win preliminary nod for 2 GLP-1 drugs in China

Pfizer's Ecnoglutide and Innovent's mazdutide injection passed a preliminary review for inclusion in China's basic medical insurance drug catalogue, the National Healthcare Security Administration said Monday.

The two GLP-1 receptor agonists were listed among candidates that cleared the initial screening stage for potential government reimbursement, according to the NHSA's published list. The review process evaluates drugs based on clinical efficacy, cost-effectiveness, and patient need before a final decision is made.

Ecnoglutide, a once-weekly GLP-1 injection developed by Pfizer, and mazdutide, Innovent's dual GLP-1/glucagon receptor agonist, target the diabetes and obesity treatment market. China's GLP-1 market has attracted global pharmaceutical companies including Novo Nordisk, whose Ozempic and Wegovy dominate the segment, and Eli Lilly with Mounjaro and Zepbound.

Inclusion in the national catalog would make the drugs accessible to a broader patient population through government reimbursement, potentially accelerating adoption in a market where out-of-pocket costs limit uptake. China is the world's second-largest pharmaceutical market by spending.

The preliminary approval gives Pfizer and Innovent a foothold to compete in that market, though final inclusion and pricing terms remain subject to negotiation. A final decision on catalog inclusion is expected later this year, with price talks to follow. For Pfizer, the nod marks progress in its GLP-1 strategy after the company faced setbacks in the oral GLP-1 race. For Innovent, mazdutide represents a potential blockbuster in its metabolic pipeline.

This article is for informational purposes only and does not constitute investment advice.